MPL and autoimmune thrombocytopenic purpura: Romiplostim and eltrombopag are thrombopoietin receptor agonists which exhibit their action by inducing proliferation and differentiation of megakaryocyte progenitors, maturation of megakaryocytes and increased platelet production.72 They have displayed excellent results in phase III randomized trials73,74 and have been approved since 2008 as second line agents for ITP refractory to other treatments.